SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of PSS World Medical, Inc. In Connection With The Sale Of The Company To McKesson Corporation

Levi & Korsinsky is investigating the Board of Directors of PSS World Medical, Inc. (“PSSI” or the “Company”) (NasdaqGS: PSSI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to McKesson Corporation (NYSE: MCK).

Click here to learn more about the investigation: http://zlk.9nl.com/pss-world-medical-pssi, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, PSSI shareholders will receive $29.00 for each share of PSSI stock they own. The transaction has a total approximate value of $2.1 billion. The investigation concerns whether the PSSI Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before entering into this transaction and whether McKesson Corporation is underpaying for PSSI shares, thus unlawfully harming PSSI stockholders.

If you own common stock in PSSI and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/pss-world-medical-pssi.

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

PSS World Medical Stock Hits New 52-Week High (PSSI)

PSS World Medical Reaches New 52-Week High (PSSI)

PSS World Medical Stock Hits New 52-Week High (PSSI)

Stocks Finish With Mild Gains

3 Hot Stocks to Trade (or Not)